v3.26.1
Stockholders Equity (Tables)
 3 Months Ended
Mar. 31, 2026
Stockholders Equity [Line Items]  
Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders

As of March 31, 2026, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:

 

Warrant  Issuance Date  Expiration Date  Exercise Price Per Share   Number of Shares of Common Stock Underlying Warrants 
               
2021 Registered Direct Offering Warrants  July 28, 2021  January 28, 2027   950.00    14,808 
Merger Warrants  March 15, 2024  January 28, 2027   950.00    11,404 
Private Placement Warrants  March 15, 2024  July 9, 2026   43.91    203,444 
Registered Pre-Funded Warrants  February 25, 2025  April 21, 2030   0.0019    42,381 
Private Pre-Funded Warrants  February 25, 2025  April 21, 2030   0.0019    46,232 
Common Warrants  February 25, 2025  April 21, 2030   17.68    312,503 
Inducement Warrants  February 25, 2025  April 21, 2030   17.68    366,087 
A&R Warrants  February 25, 2025  April 21, 2030   0.0019    157,603 
               1,154,462 

As of March 31, 2026, the Company had the following outstanding compensation related warrants to purchase Common Stock:

 

Warrant  Issuance Date  Expiration Date   Exercise
Price Per
Share		   Number of
Shares of
Common Stock
Underlying
Warrants		 
Private Warrants issued to scientific founders*  November 27, 2017   
-
    
-
    16 
Landlord Warrants  March 15, 2024   January 28, 2027    950.00    1,316 
Agents Warrants  March 15, 2024   July 9, 2026    43.91    50,126 
January 2026 private placement agent warrants  January 13, 2026   January 12, 2031    2.50    99,000 
                 150,458 

 

*In November 2017, BiomX Israel issued 298 warrants to its founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price.
Schedule of Options Granted to Purchase the Company’s Common Stock Under the Company’s Share Option Plans

A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:

 

   For the Three Months Ended March 31, 2026 
   Number of Options   Weighted Average Exercise Price   Aggregate Intrinsic Value 
Outstanding at the beginning of period   150,387   $77.71   $
-
 
Granted   
-
    
-
    - 
Forfeited   107,579    36.68    - 
Expired   1,712    32.53    - 
Exercised   
-
    
-
      
Outstanding at the end of period   41,096    92.45   $1 
Exercisable at end of period   41,096    92.45      
Weighted average remaining contractual life – years as of March 31, 2026   7.96           
Schedule of Stock-Based Payment Expenses

The following table sets forth the total stock-based payment expenses resulting from options, RSUs and warrants granted, included in the consolidated statements of operations:

 

   Three Months Ended
March 31,		 
   2026   2025 
         
Research and development expenses, net   (647)   188 
General and administrative   (1,281)   471 
    (1,928)   659